Rigel Pharmaceuticals Inc
SWB:RI2A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Rigel Pharmaceuticals Inc
SWB:RI2A
|
US |
|
Rumble Inc
NASDAQ:RUM
|
US |
|
Mizuho Financial Group Inc
TSE:8411
|
JP |
|
Main Street Capital Corp
NYSE:MAIN
|
US |
|
D
|
Dis-Chem Pharmacies Ltd
JSE:DCP
|
ZA |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
US |
|
S
|
SosTravel.com SpA
MIL:SOS
|
IT |
|
APi Group Corp
NYSE:APG
|
US |
|
C
|
CNFinance Holdings Ltd
NYSE:CNF
|
CN |
Wall St Price Targets
RI2A Price Targets Summary
Rigel Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RI2A is 13.119 EUR with a low forecast of 9.717 EUR and a high forecast of 18.344 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RI2A's stock price target?
Price Target
13.119
EUR
According to Wall Street analysts, the average 1-year price target for RI2A is 13.119 EUR with a low forecast of 9.717 EUR and a high forecast of 18.344 EUR.
What is the Revenue forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Revenue has been 45%. The projected CAGR for the next 8 years is -2%.
What is the Operating Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
0%
The compound annual growth rate for Operating Income over the next 8 years is 0%.
What is the Net Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-16%
The compound annual growth rate for Net Income over the next 8 years is -16%.
